|
National Advisory Committee on Immunization (NACI)
Terms of Reference1.0 Background 1.0 BACKGROUNDThe National Advisory Committee on Immunizing Agents was initially established in 1964 to report to the Dominion Council of Health. Its purpose was “to advise and make recommendations on immunizing agents” and “...to propose to the Council aspects of immunizing agents that appear to warrant special consideration”. The first meeting of the Committee was held in November 1964. From 1975 to 2000, the Committee reported to the Assistant Deputy Minister, Health Protection Branch. The Committee's name was formally changed to the NACI in June 1978. From 2000-2004 the Committee reported to the Assistant Deputy Minister, Population and Public Health Branch (PPHB), following a restructuring within Health Canada. Since October 2004, the NACI reports to the Chief Public Health Officer, Public Health Agency of Canada (PHAC). Since 1999, the Advisory Committee on Population Health and Health Security (ACPHHS) has supported the development of a strategy to address immunization issues in Canada, the National Immunization Strategy (NIS). In June 2003, The Conference of F/P/T Deputy Ministers of Health (CDMH) has accepted the final report on the National Immunization Strategy as advice in moving forward with immunization issues in Canada. An advisory committee to the PHAC, the Canadian Immunization Committee (CIC) was established as the mechanism for making continued, collaborative progress to address immunization issues in Canada. The CIC is the means to effect F/P/T collaboration for the purpose of providing leadership in immunization through the analysis, development and recommendation of national goals, effective and efficient immunization programs, policies, practices, guidelines and standards. The NACI is directly linked to the CIC and part of an overall national structure dealing with immunization issues in Canada. 2.0 MANDATETo provide the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to vaccines and certain prophylaxis agents (e.g., immunoglobulins and antivirals). More specifically, advice may relate to the use of vaccines in humans, vaccine evaluation, and the monitoring of vaccine-associated adverse events. 3.0 ROLES AND RESPONSIBILITIESWithout limiting the foregoing, the Committee will carry out its mandate in the following manner: 3.1 Advising the PHAC on vaccine use by:
3.2 Advising the PHAC on vaccine research and surveillance by:
3.3 Advising the PHAC and the CIC on vaccine programs by:
4.0 GOVERNANCE4.1 Reporting Relationship:
4.2 Membership 4.2.1 Chair 4.2.2 Vice-Chair 4.2.3 Executive Secretary 4.2.4 Members The membership will be reviewed on a regular basis by the Chair and Executive Secretary. Suggestions will be sought from current and former NACI members. A list of potential nominees will be maintained by the Secretariat. The candidate remains on the list until withdrawn or nominated to the committee. In appropriate circumstances, the CPHO may extend an individual's term of office for up to another four years. When a member is unable to complete his or her term, a letter of resignation should be submitted to the Chair of the committee and the CPHO via the Secretariat. A new member will be appointed for the full four-year term. 4.2.5 Liaison Groups 4.2.6 Ex-officio Members 5.0 VOTING AND QUORUMVoting will be restricted to the twelve members only. A quorum of at least 50% of members is required to authenticate a vote. Members who have been absent for all discussions and not able to review all background documentation will not be permitted to vote in advance of meetings or calls. An abstention will count as a neutral vote. Where there is a tie, the Chair can cast the deciding vote. 6.0 RESOURCES AND SUPPORTSecretariat functions to the committee (or working group) will be provided by the PHAC. Scientific, research, policy, monitoring, and other technical support will be provided and/or funded by the PHAC, IRID, CIDPC. The members' travel expenses to participate at regular and ad hoc NACI meetings will be paid by the PHAC in accordance with Treasury Board Policies. Liaison representatives and Ex-officio members will be expected to pay for their travel expenses. 7.0 MEETINGSNACI meets three times a year and by teleconference on a need basis. 7.1 Attendance Liaison representatives will be encouraged to attend all meetings. Should they be unable to attend a meeting, they can assign an alternate. 7.2 Record of Decisions For each meeting, Record of Decisions will also be prepared by the Secretariat. Once reviewed by the Chair/Executive Secretary it will be distributed to the members/liaison representatives/Ex-officio members. Upon approval by all NACI members a final version of the Record of Decisions will be sent to all as a Confidential document. 7.3 Invitees 7.4 Selection of topics (on a needs basis)
8.0 PRIVACY OF INFORMATIONMatters discussed at the meeting are confidential and should not be discussed by members in public until they are so permitted by the PHAC. Reports to respective associations by liaison members should be in general terms only and should be maintained in confidence by that member's organization. All members are required to sign confidentiality agreements. The draft NACI statements should not be shared. However, in some cases it may be acceptable to share information on the general directions that NACI is going with a statement. In an event that it would be useful to share a draft statement with specific groups for feedback, the Chair and Executive Secretary should be consulted. 9.0 MEDIA INTERACTIONAll media request related to NACI statements or activities should be directed to the PHAC, Media Relations Division. Media response will be coordinated by the PHAC. More detailed guidelines will be developed by the Secretariat and reviewed on a regular basis. 10. CONFLICT OF INTERESTMembers, representatives and consultants are expected to conduct themselves in an appropriate manner. They must refrain from any real or perceived conflict of interest. In situations where conflict of interest, or the appearance thereof, arises in the course of the work of a committee, the individual involved must declare its existence and disqualify himself/herself from participation in the discussion or from further participation on the committee according to the circumstances of specific situations. Prior to of each meeting, members will be given an opportunity to advise on any potential conflict of interest. Members, liaison representatives and consultants will be required to submit annual conflict of interest declarations to the Executive Secretary and disclose any circumstances that may place, or be seen to place the member in a real, apparent or potential conflict of interest. It will be incumbent upon the member to update their disclosure in writing, should their personal situation change. Members, representatives and consultants are expected to protect and maintain as confidential any trade secret or privileged information divulged during the work of the committee. They must not discuss or divulge information obtained from the work of the committee, including its recommendations, until such time as this information has been officially released by the PHAC for public distribution. 11.0 RECOMMENDATIONS11.1 Development Process Smaller working groups will be established to deal with specific vaccine-related issues. Working groups chairs should be members of NACI or as deemed appropriate by the Committee Chair. Members will be asked to volunteer to participate in working groups based on their expertise. A working group membership list will be maintained by the Secretariat and reviewed on a regular basis. Working groups will review technical aspects and prepare recommendations to be discussed by the full committee. These working groups must include one or more regular voting members as well as one staff member of the PHAC. They may also include liaison members or other consultants. Experts, including representatives from manufacturers, may be invited to present to the group but may not join the group or participate in group discussions. The process of developing NACI recommendations includes:
The methods used for developing recommendations will be made explicit in the published recommendations. 11.2 Publication of Recommendations 12.0 TERMS OF REFERENCEMinor Amendments to the Terms of Reference can be made by the Executive Secretary, in consultation with the Chair, subject to informing the members at the next meeting. The Terms of Reference may be amended at any meeting by consensus or by vote.
|
Last Updated: 2005-09-06 |